{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T07:24:58Z","timestamp":1795073098662,"version":"4.10.2"},"reference-count":46,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Research Councils UK","doi-asserted-by":"publisher","award":["MR\/M026647\/1"],"award-info":[{"award-number":["MR\/M026647\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["13082029517"],"award-info":[{"award-number":["13082029517"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin\u2013angiotensin\u2013aldosterone system, respectively. They play an important role in blood pressure regulation and reducing the risk of heart failure. Vasopeptidase inhibitors omapatrilat and sampatrilat possess dual activity against these enzymes by blocking the ACE-dependent conversion of angiotensin I to the potent vasoconstrictor angiotensin II while simultaneously halting the NEP-dependent degradation of vasodilator atrial natriuretic peptide. Here, we report crystal structures of omapatrilat, sampatrilat, and sampatrilat-ASP (a sampatrilat analogue) in complex with NEP at 1.75, 2.65, and 2.6 \u00c5, respectively. A detailed analysis of these structures and the corresponding structures of ACE with these inhibitors has provided the molecular basis of dual inhibitor recognition involving the catalytic site in both enzymes. This new information will be very useful in the design of safer and more selective vasopeptidase inhibitors of NEP and ACE for effective treatment in hypertension and heart failure.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.0c00441","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T05:38:01Z","timestamp":1587965881000},"page":"5488-5500","source":"Crossref","is-referenced-by-count":25,"title":["Molecular Basis\nfor Omapatrilat and Sampatrilat Binding\nto Neprilysin\u2500Implications for Dual Inhibitor Design with Angiotensin-Converting\nEnzyme"],"prefix":"10.1021","volume":"63","author":[{"given":"Urvashi","family":"Sharma","sequence":"first","affiliation":[{"name":"University of Bath , , Claverton Down, ,","place":["Bath, United Kingdom, BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyles E.","family":"Cozier","sequence":"additional","affiliation":[{"name":"University of Bath , , Claverton Down, ,","place":["Bath, United Kingdom, BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Sturrock","sequence":"additional","affiliation":[{"name":"University of Cape Town , , Observatory , ,","place":["Cape Town, Republic of South Africa, 7935"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3009-4058","authenticated-orcid":true,"given":"K. Ravi","family":"Acharya","sequence":"additional","affiliation":[{"name":"University of Bath , , Claverton Down, ,","place":["Bath, United Kingdom, BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"2026090305460532400_cit1","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1097\/HJH.0000000000002021","article-title":"The global\nburden of hypertension exceeds 1.4 billion people: should a systolic\nblood pressure target below 130 become the universal standard?","volume":"37","author":"Egan","year":"2019","journal-title":"J. Hypertens."},{"key":"2026090305460532400_cit2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"key":"2026090305460532400_cit3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/000155501317140007","article-title":"Angiotensin-converting enzyme inhibitors\nas inducers\nof adverse cutaneous reactions","volume":"81","author":"Steckelings","year":"2001","journal-title":"Acta Derm.-Venereol."},{"key":"2026090305460532400_cit4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/HYPERTENSIONAHA.108.111393","article-title":"Angiotensin-converting\nenzyme inhibitors and angioedema:\nestimating the risk","volume":"51","author":"Weber","year":"2008","journal-title":"Hypertension"},{"key":"2026090305460532400_cit5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/pr.118.017129","article-title":"Novel therapeutic\napproaches targeting the renin-angiotensin system and associated peptides\nin hypertension and heart failure","volume":"71","author":"Arendse","year":"2019","journal-title":"Pharmacol.\nRev."},{"key":"2026090305460532400_cit6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1592\/phco.22.1.27.33502","article-title":"A review of vasopeptidase\ninhibitors: a new modality\nin the treatment of hypertension and chronic heart failure","volume":"22","author":"Nathisuwan","year":"2002","journal-title":"Pharmacotherapy"},{"key":"2026090305460532400_cit7","first-page":"2","article-title":"Vasopeptidase inhibitors:\npotential role in the treatment\nof heart failure","volume":"2","author":"Trindade","year":"2001","journal-title":"Heart Failure Monit."},{"key":"2026090305460532400_cit8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(01)06584-9","article-title":"Vasopeptidase\ninhibitors","volume":"358","author":"Weber","year":"2001","journal-title":"Lancet"},{"key":"2026090305460532400_cit9","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1021\/acs.jmedchem.8b01309","article-title":"Molecular\nbasis for multiple omapatrilat binding sites within the ACE C-domain:\nImplications for drug design","volume":"61","author":"Cozier","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026090305460532400_cit10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1021\/jm970041e","article-title":"Dual metalloprotease\ninhibitors:\nmercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors\nof angiotensin-converting enzyme and neutral endopeptidase","volume":"40","author":"Robl","year":"1997","journal-title":"J. Med. Chem."},{"key":"2026090305460532400_cit11","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1161\/01.HYP.35.6.1226","article-title":"In vitro and in vivo\ninhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase\ninhibitor","volume":"35","author":"Azizi","year":"2000","journal-title":"Hypertension"},{"key":"2026090305460532400_cit12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients\nwith hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril\n(OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"2026090305460532400_cit13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect\nof bradykinin metabolism inhibitors\non evoked hypotension in rats: rank efficacy of enzymes associated\nwith bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br. J.\nPharmacol."},{"key":"2026090305460532400_cit14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1476-5381.1996.tb15763.x","article-title":"Renal effects of\nconcurrent E-24.11 and ACE inhibition\nin the aorto-venocaval fistula rat","volume":"119","author":"Kirk","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"2026090305460532400_cit15","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1021\/acs.jcim.6b00524","article-title":"The dynamic nonprime binding of sampatrilat\nto the C-domain of angiotensin-converting enzyme","volume":"56","author":"Sharma","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"2026090305460532400_cit16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0731-7085(97)00127-1","article-title":"Clinical\nanalysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting\nenzyme inhibitor II: assay in the plasma and urine of human volunteers\nby dissociation enhanced lanthanide fluorescence immunoassay (DELFIA)","volume":"16","author":"Venn","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2026090305460532400_cit17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0731-7085(97)00126-X","article-title":"Clinical analysis\nof sampatrilat, a combined renal endopeptidase and angiotensin-converting\nenzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure\nionisation mass-spectrometry following derivatisation with BF3-methanol","volume":"16","author":"Venn","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2026090305460532400_cit18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0009-9236(98)90075-3","article-title":"Combined inhibition\nof neutral endopeptidase\nand angiotensin-converting enzyme by sampatrilat in essential hypertension","volume":"64","author":"Wallis","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026090305460532400_cit19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1042\/BJ20100056","article-title":"Characterization\nof domain-selective inhibitor binding in angiotensin-converting enzyme\nusing a novel derivative of lisinopril","volume":"428","author":"Watermeyer","year":"2010","journal-title":"Biochem.\nJ."},{"key":"2026090305460532400_cit20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20130808","article-title":"Effects\nof a domain-selective ACE inhibitor in a mouse\nmodel of chronic angiotensin II-dependent hypertension","volume":"127","author":"Burger","year":"2014","journal-title":"Clin. Sci."},{"key":"2026090305460532400_cit21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1161\/01.HYP.31.4.912","article-title":"N-domain-specific\nsubstrate and C-domain inhibitors\nof angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE","volume":"31","author":"Deddish","year":"1998","journal-title":"Hypertension"},{"key":"2026090305460532400_cit22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/1470320314568438","article-title":"Pharmacodynamic\neffects of C-domain-specific ACE inhibitors on the renin-angiotensin\nsystem in myocardial infarcted rats","volume":"16","author":"Sharp","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone\nSyst."},{"key":"2026090305460532400_cit23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/febs.14421","article-title":"Crystal structures\nof sampatrilat and sampatrilat-Asp\nin complex with human ACE - a molecular basis for domain selectivity","volume":"285","author":"Cozier","year":"2018","journal-title":"FEBS J."},{"key":"2026090305460532400_cit24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1107\/S2053230X19006046","article-title":"Structures\nof soluble rabbit neprilysin\ncomplexed with phosphoramidon or thiorphan","volume":"75","author":"Labiuk","year":"2019","journal-title":"Acta Crystallogr., Sect. F: Struct. Biol. Commun."},{"key":"2026090305460532400_cit25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/jmbi.1999.3492","article-title":"Structure\nof human neutral endopeptidase (Neprilysin) complexed with phosphoramidon","volume":"296","author":"Oefner","year":"2000","journal-title":"J. Mol. Biol."},{"key":"2026090305460532400_cit26","doi-asserted-by":"publisher","DOI":"10.1038\/srep27909","article-title":"Structure\nof neprilysin in complex with the active metabolite of\nsacubitril","volume":"6","author":"Schiering","year":"2016","journal-title":"Sci. Rep."},{"key":"2026090305460532400_cit27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1124\/jpet.115.231167","article-title":"Pharmacologic comparison of clinical neutral endopeptidase\ninhibitors in a rat model of acute secretory diarrhea","volume":"357","author":"Griggs","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026090305460532400_cit28","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1097\/00005344-199506263-00021","article-title":"Differential structure-activity relationships\nof phosphoramidon analogues for inhibition of three metalloproteases:\nendothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting\nenzyme","volume":"26","author":"Kukkola","year":"1995","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2026090305460532400_cit29","doi-asserted-by":"publisher","first-page":"12569","DOI":"10.1021\/bi991043z","article-title":"Crystal\nstructures of alpha-mercaptoacyldipeptides\nin the thermolysin active site: structural parameters for a Zn monodentation\nor bidentation in metalloendopeptidases","volume":"38","author":"Gaucher","year":"1999","journal-title":"Biochemistry"},{"key":"2026090305460532400_cit30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/jm960583g","article-title":"Meta-substituted benzofused macrocyclic lactams as\nzinc metalloprotease inhibitors","volume":"40","author":"Ksander","year":"1997","journal-title":"J. Med. Chem."},{"key":"2026090305460532400_cit31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1021\/jm960582o","article-title":"Ortho-substituted benzofused macrocyclic\nlactams as zinc metalloprotease inhibitors","volume":"40","author":"Ksander","year":"1997","journal-title":"J. Med. Chem."},{"key":"2026090305460532400_cit32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/protein\/12.2.141","article-title":"A three-dimensional\nconstruction\nof the active site (region 507-749) of human neutral endopeptidase\n(EC.3.4.24.11)","volume":"12","author":"Tiraboschi","year":"1999","journal-title":"Protein Eng., Des. Sel."},{"key":"2026090305460532400_cit33","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1016\/S0021-9258(18)98378-X","article-title":"Differences\nin the properties and enzymatic specificities\nof the two active sites of angiotensin I-converting enzyme (kininase\nII). Studies with bradykinin and other natural peptides","volume":"268","author":"Jaspard","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2026090305460532400_cit34","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1021\/bi700275e","article-title":"The structure of\ntestis angiotensin-converting enzyme in complex with the C-domain\nspecific inhibitor RXPA380","volume":"46","author":"Corradi","year":"2007","journal-title":"Biochemistry"},{"key":"2026090305460532400_cit35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1021\/jm9010803","article-title":"Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain\nand endothelin-converting enzyme-1 inhibitors","volume":"53","author":"Jullien","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090305460532400_cit36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsb.2018.06.004","article-title":"High resolution crystal structure\nof substrate-free human neprilysin","volume":"204","author":"Moss","year":"2018","journal-title":"J. Struct.\nBiol."},{"key":"2026090305460532400_cit37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1107\/S2059798316002187","article-title":"Diffraction-geometry\nrefinement in the DIALS framework","volume":"72","author":"Waterman","year":"2016","journal-title":"Acta Crystallogr.,\nSect. D: Struct. Biol."},{"key":"2026090305460532400_cit38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good\nare my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta\nCrystallogr., Sect. D: Biol. Crystallogr."},{"key":"2026090305460532400_cit39","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1107\/S0907444994003112","article-title":"The CCP4 suite: programs for protein crystallography","volume":"50","author":"Collaborative Computational Project Number 4.","year":"1994","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"2026090305460532400_cit40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"2026090305460532400_cit41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement\nof macromolecular structures\nby the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr.,\nSect. D: Biol. Crystallogr."},{"key":"2026090305460532400_cit42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based\nsystem for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"2026090305460532400_cit43","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular\ngraphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr., Sect. D: Biol.\nCrystallogr."},{"key":"2026090305460532400_cit44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular\ncrystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr., Sect. D:\nBiol. Crystallogr."},{"key":"2026090305460532400_cit45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1107\/S0907444911007281","article-title":"Presenting your\nstructures: the CCP4mg molecular-graphics software","volume":"67","author":"McNicholas","year":"2011","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"2026090305460532400_cit46","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand-protein\ninteraction diagrams\nfor drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.0c00441","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/10\/5488\/67201468\/acs.jmedchem.0c00441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/10\/5488\/67201468\/acs.jmedchem.0c00441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:46:16Z","timestamp":1788428776000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/63\/10\/5488\/1536791\/Molecular-Basis-for-Omapatrilat-and-Sampatrilat"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,4,27]]},"published-print":{"date-parts":[[2020,5,28]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00441","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00441.s001","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]}}}